scholarly journals Reasoning with linguistic preferences using NPN logic

2010 ◽  
Vol 7 (3) ◽  
pp. 511-528 ◽  
Author(s):  
Goran Devedzic ◽  
Danijela Milosevic ◽  
Lozica Ivanovic ◽  
Dragan Adamovic ◽  
Miodrag Manic
Keyword(s):  
Side Effects ◽  
Decision Analysis ◽  
Decision Maker ◽  
Real World ◽  
Cognitive Maps ◽  
Fuzzy Cognitive Maps ◽  
Basic Notion ◽  
The Real ◽  
Alternative Framework ◽  
Linguistic Models

Negative-positive-neutral logic provides an alternative framework for fuzzy cognitive maps development and decision analysis. This paper reviews basic notion of NPN logic and NPN relations and proposes adaptive approach to causality weights assessment. It employs linguistic models of causality weights activated by measurement-based fuzzy cognitive maps? concepts values. These models allow for quasi-dynamical adaptation to the change of concepts values, providing deeper understanding of possible side effects. Since in the real-world environments almost every decision has its consequences, presenting very valuable portion of information upon which we also make our decisions, the knowledge about the side effects enables more reliable decision analysis and directs actions of decision maker.

The ontogeny of a mammalian cognitive map in the real world

Science ◽  
2020 ◽  
Vol 369 (6500) ◽  
pp. 194-197 ◽  
Author(s):  
Lee Harten ◽  
Amitay Katz ◽  
Aya Goldshtein ◽  
Michal Handel ◽  
Yossi Yovel
Keyword(s):  
Real World ◽  
Large Scale ◽  
Cognitive Maps ◽  
Cognitive Map ◽  
Interindividual Differences ◽  
The Real ◽  
Fruit Bat ◽  
Wild Fruit ◽  
In The Wild

How animals navigate over large-scale environments remains a riddle. Specifically, it is debated whether animals have cognitive maps. The hallmark of map-based navigation is the ability to perform shortcuts, i.e., to move in direct but novel routes. When tracking an animal in the wild, it is extremely difficult to determine whether a movement is truly novel because the animal’s past movement is unknown. We overcame this difficulty by continuously tracking wild fruit bat pups from their very first flight outdoors and over the first months of their lives. Bats performed truly original shortcuts, supporting the hypothesis that they can perform large-scale map-based navigation. We documented how young pups developed their visual-based map, exemplifying the importance of exploration and demonstrating interindividual differences.

Fuzzy Rationality in Quantitative Decision Analysis

2005 ◽  
Vol 9 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Natalia Nikolova ◽  
◽  
Aleksei Shulus ◽  
Daniela Toneva ◽  
Kiril Tenekedjiev ◽  
...  
Keyword(s):  
Decision Analysis ◽  
Decision Maker ◽  
Decision Makers ◽  
Actual Process ◽  
Subjective Probabilities ◽  
Uncertainty Interval ◽  
The Real ◽  
Elicitation Process ◽  
The One

The paper presents a discussion on fuzzy rationality in the elicitation of subjective probabilities and utilities. In addition to previous research, two functions, measuring the degree of preference of the real decision maker on both sides of the uncertainty interval are introduced, and their relationship with the indifference function, measuring the degree of indifference of the decision maker over gambles, is analyzed and graphically interpreted. A new relation -- hesitation -- is introduced to give a better description of the actual process of subjective elicitation by real decision makers. The influence of the preference-hesitation combination in an elicitation process is presented graphically, and it is argued that the resulting uncertainty interval is much tighter than the one, resulting from the preference-indifference based elicitation.

Children's Social Participation in Virtual Worlds

2013 ◽  
Vol 5 (4) ◽  
pp. 59-73 ◽  
Author(s):  
Terhi Tuukkanen ◽  
Terhi-Anna Wilska ◽  
Ahmer Iqbal ◽  
Marja Kankaanranta
Keyword(s):  
Side Effects ◽  
Social Participation ◽  
Virtual Worlds ◽  
Real World ◽  
Social Practice ◽  
Social Practices ◽  
The Real ◽  
Interviewing Children

Virtual worlds provide an arena for children to express themselves and to interact with others. They are a natural and frequent part of children's life today. However, there is not much research on what actually happens in the online worlds and what kind of opportunities those worlds could offer to children and thereby enhance their social participation. The aim in this study is to explore the potential of virtual worlds for children's social participation. The empirical part of the study consists of interviews with 21 Finnish children, aged 11-15 years. By interviewing children, the authors examined their social practices in virtual worlds. In the study, the authors found seven types of social practice that make it possible for children to socialize with others, learn new things and skills, express themselves publicly and play in virtual worlds. Virtual worlds provide an arena for children to overcome the limitations of the real world. However, the freedom also has side effects: misbehavior.

Efficacy and safety of PCSK9-Inhibitors in the real-world: data from a clinical registry

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P.S Saba ◽  
A Murgia ◽  
E Gazale ◽  
P Terrosu ◽  
G.D Sanna ◽  
...  
Keyword(s):  
Side Effects ◽  
Real World ◽  
Ldl Cholesterol ◽  
Geographical Area ◽  
University Hospital ◽  
Efficacy And Safety ◽  
Pcsk9 Inhibitors ◽  
The Real ◽  
Number Of Patients

Abstract Background To date, little information is available on the real impact of PCSK9 inhibitors in terms of reducing cholesterolemia, events and the actual tolerability in the so-called “real world”. This lack of information is substantially related to the fact that these drugs have only been marketed recently. In Italy, few centres are licensed to prescribe these drugs. This, on the one hand, limited the number of patients to whom the new therapy was offered but, on the other hand, “concentrated” the observations in a few centres, making it possible to more easily collect the few data currently available. The Cardiology Unit of our university hospital is the only prescribing centre in the North Sardinia and therefore represents the natural collector of all the prescriptions of this drug in this wide geographical area. Purpose The aim of the study was to evaluate the efficacy and tolerability of PCSK9 inhibitors in the current clinical practice. Methods Data were collected reviewing all Alirocumab and Evolocumab prescriptions provided by the Cardiology Unit of our university hospital included in the Italian National Drug Agency (AIFA) registry from February 2017 to October 2019. In order to collect complete clinical information, all patients were interviewed regarding their health status, the on-treatment cholesterol levels and the possible appearance of side effects or cardiovascular events. Results In the reference period, 111 patients (58.9% males, age 63±10 years) received PCSK9-Inhibitors prescription (52.7% Evolocumab, 47.3% Alirocumab), 86.5% as secondary prevention. Statin intolerance was the indication for PCSK9-Inhibitors in the majority (73.3%) of patients. LDL cholesterol at eligibility evaluation was 175±50 mg/dl and reduced to 87±44 mg/dl (p<0.0001) at last follow-up assessment (median 12.3 IQR 6.8–21.4 years). Maximal per cent variation of LDL-cholesterol was achieved already after 6 months of therapy (−45±3% vs basal). No attenuation in LDL-cholesterol lowering was observed; conversely, LDL levels continued to reduce during treatment (p for linear trend = 0.01; Figure 1). During follow-up, 8 patients (7.2%) stopped PCSK9 inhibitors: 2 subjects (1.8%) for side effects certainly related to the drug (flu-like syndrome, allergic reaction), 4 for possible side effects (myalgia, abdominal pain), the remaining for other reasons. Conclusions Clinical use of PCSK9 inhibitors confirms its efficacy and safety also in the “real world” setting. LDL reduction occurs early during the treatment and shows a significant trend in further reduction during the observation period. More than 90% of subjects tolerate and persist in PCSK9 inhibitors treatment in the long-term follow-up. Figure 1 Funding Acknowledgement Type of funding source: None

scholarly journals The side effect profile of Clozapine in real world data of three large mental health hospitals

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243437
Author(s):  
Ehtesham Iqbal ◽  
Risha Govind ◽  
Alvin Romero ◽  
Olubanke Dzahini ◽  
Matthew Broadbent ◽  
...  
Keyword(s):  
Mental Health ◽  
Side Effects ◽  
Adverse Effects ◽  
Hospital Admission ◽  
Real World ◽  
Smoking Status ◽  
Monthly Interval ◽  
Real World Data ◽  
Significance Level ◽  
The Real

Objective Mining the data contained within Electronic Health Records (EHRs) can potentially generate a greater understanding of medication effects in the real world, complementing what we know from Randomised control trials (RCTs). We Propose a text mining approach to detect adverse events and medication episodes from the clinical text to enhance our understanding of adverse effects related to Clozapine, the most effective antipsychotic drug for the management of treatment-resistant schizophrenia, but underutilised due to concerns over its side effects. Material and methods We used data from de-identified EHRs of three mental health trusts in the UK (>50 million documents, over 500,000 patients, 2835 of which were prescribed Clozapine). We explored the prevalence of 33 adverse effects by age, gender, ethnicity, smoking status and admission type three months before and after the patients started Clozapine treatment. Where possible, we compared the prevalence of adverse effects with those reported in the Side Effects Resource (SIDER). Results Sedation, fatigue, agitation, dizziness, hypersalivation, weight gain, tachycardia, headache, constipation and confusion were amongst the highest recorded Clozapine adverse effect in the three months following the start of treatment. Higher percentages of all adverse effects were found in the first month of Clozapine therapy. Using a significance level of (p< 0.05) our chi-square tests show a significant association between most of the ADRs and smoking status and hospital admission, and some in gender, ethnicity and age groups in all trusts hospitals. Later we combined the data from the three trusts hospitals to estimate the average effect of ADRs in each monthly interval. In gender and ethnicity, the results show significant association in 7 out of 33 ADRs, smoking status shows significant association in 21 out of 33 ADRs and hospital admission shows the significant association in 30 out of 33 ADRs. Conclusion A better understanding of how drugs work in the real world can complement clinical trials.

scholarly journals ACT-09 RETROSPECTIVE INVESTIGATION ABOUT STATUS AND RESULT OF ADMINISTRATION OF BEVACIZUMAB FOR MALIGNANT GLIOMAS IN THE REAL WORLD

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii13-ii14
Author(s):  
Tetsuo Hashiba ◽  
Katsuya Ueno ◽  
Nobuaki Naito ◽  
Mayuko Miyata ◽  
Natsumi Yamamura ◽  
...  
Keyword(s):  
Side Effects ◽  
Real World ◽  
Side Effect ◽  
Initial Treatment ◽  
Malignant Gliomas ◽  
Initial Therapy ◽  
Partial Resection ◽  
The Real ◽  
Retrospective Investigation ◽  
Excision Rate

Abstract 6 years have passed after approval of Bevacizumab for malignant gliomas in Japan, we analyzed the application and the results in our institution. Subjects were 56 patients who were histologically diagnosed as malignant gliomas. Bevacizumab was used in 41 patients among them. In 14 patients, Bevacizumab was introduced after initial therapy. The resection rates were below partial resection in 11 of the 14 patients. In 12 patients, administrations were finished and the average use was 7.6 times. The reason was PD in 6, and side effect in 4. Eight patients died, the average OS of those who died was 9.9 months, the average PFS after Bevacizumab was 5.4 months, and the average time from discontinuation to death was 2.1 months. In 27 patients used at the time of recurrence, the initial excision rate tended to be higher than in the former cases. In 22 patients the administrations were finished and the average use was 11.1 times. The reason was PD in 17, and side effect in 4. Twenty patients have died, the average OS of those who died was 22.3 months, the average PFS after Bevacizumab was 7.1 months, and the average time from discontinuation to death was 2.6 months. In 12 of 15 unused patients subtotal or total resections were achieved. From results, when it is difficult to control by surgery or TMZ, Bevacizumab is used in most patients, and considering the nature of tumor, it can be said that all patients will be considered for use sometime. However, PFS after introduction is not good and the prognosis after discontinuation is poor. It is necessary to conduct initial treatment that can delay introduction, to provide care that does not lead to discontinuation due to side effects, and to examine what treatment is possible at the time of exacerbation.

scholarly journals Safety and Use of MLC601/MLC901 (NeuroAiDTM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry

2020 ◽  
Vol 10 (8) ◽  
pp. 499
Author(s):  
Ramesh Kumar ◽  
Azizi Abu Bakar ◽  
Jegan Thanabalan ◽  
Sanmugarajah Paramasvaran ◽  
Charng Jeng Toh ◽  
...  
Keyword(s):  
Cohort Study ◽  
Side Effects ◽  
Intracerebral Hemorrhage ◽  
Real World ◽  
Brain Injuries ◽  
Neurological Recovery ◽  
Safe Treatment ◽  
The Real ◽  
Real World Setting ◽  
Concentration Test

Background: MLC601/MLC901 (NeuroAiD™) is a combination of natural products shown to be safe and to aid neurological recovery after brain injuries, especially ischemic stroke. Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH). The NeuroAiD Safe Treatment (NeST) Registry explores NeuroAiD use in the real-world setting. This cohort study aimed to assess its use and safety in ICH. Methods: The online NeST Registry of subjects with ICH given NeuroAiD prospectively collected clinical data at baseline and monthly visits (V) 1 to 3. Outcome measures included compliance, side effects, Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Short Orientation-Memory-Concentration Test (SOMCT). Results: Sixty-six subjects were included. NeuroAiD was well-tolerated with fair compliance over three months. Two non-serious side effects were reported. Mean scores significantly improved on all outcome scales. The proportion of subjects with favorable outcomes significantly improved from baseline to V3: NIHSS 0–4, from 12% to 59% (p < 0.0001); GCS 13–15, from 64% to 88% (p = 0.007); mRS 0–1, from 9% to 37% (p = 0.004); and SOMCT score 0–8, from 44% to 68% (p = 0.029). Conclusions: NeuroAiD in the real-world setting was safe and showed potential for a sustained positive effect on neurological recovery after ICH.

Sign in / Sign up

Export Citation Format

Share Document